4.6 Article

GSNO promotes functional recovery in experimental TBI by stabilizing HIF-1α

Journal

BEHAVIOURAL BRAIN RESEARCH
Volume 340, Issue -, Pages 63-70

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbr.2016.10.037

Keywords

TBI; GSNO; HIF-1 alpha; VEGF; Neurobehavioral function; Neurorepair; S-nitrosylation

Funding

  1. NIH [NS-72511]
  2. VA merit award [RX2090]
  3. NIH from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR018823, C06 RR015455]

Ask authors/readers for more resources

Traumatic brain injury (TBI) causes sustained disability due to compromised neurorepair mechanisms. Crucial to neurorepair and functional recovery following both TBI and stroke is hypoxia-inducible factor 1 alpha (HIF-1 alpha). Based on reports that HIF-1 alpha could be stabilized via S-nitrosylation, we tested the hypothesis that the S-nitrosylating agent S-nitrosoglutathione (GSNO) would stabilize HIF-1 alpha, thereby stimulating neurorepair mechanisms and aiding in functional recovery. TBI was induced by controlled cortical impact (CCI) in adult rats. GSNO (0.05 mg/kg) was administered at two hours after CCI. The treatment was repeated daily until the 14th day after CCI. Functional recovery was assessed by motor and cognitive functions, and the recovery was compared with the expression of HIF-1 alpha. The mechanisms of GSNO-mediated S-nitrosylation of HIF-1 alpha were determined using brain endothelial cells. While non-treated TBI animals showed sustained neurobehavioral deficits, GSNO treatment of TBI improved neurobehavioral functions. GSNO also increased the expression of HIF-1 alpha and VEGF. The beneficial effects of GSNO on neurobehavioral functions in TBI animals were blocked by treatment with the HIF-1 alpha inhibitor 2-methoxyestradiol (2-ME). The stimulatory effect of GSNO on VEGF was reversed not only by 2-ME but also by the denitrosylating agent dithiothreitol, confirming our hypothesis that GSNO's benefits are mediated by the stabilization of HIF-1 alpha via S-nitrosylation. GSNO's S-nitrosylation of HIF-1 alpha was further confirmed using a biotin switch assay in endothelial cells. The data provide evidence that GSNO treatment of TBI aids functional recovery through stabilizing HIF-1 alpha via S-nitrosylation. GSNO is a natural component of the human brain/body, and its exogenous administration has not shown adverse effects in humans. Therefore, the translational potential of GSNO therapy in TBI is high. (C) 2016 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available